Department of Microbiology and Immunology, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Master of Science Program in Tropical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan.
Viruses. 2022 Dec 29;15(1):100. doi: 10.3390/v15010100.
COVID-19, caused by SARS-CoV-2, created a devastating outbreak worldwide and consequently became a global health concern. However, no verifiable, specifically targeted treatment has been devised for COVID-19. Several emerging vaccines have been used, but protection has not been satisfactory. The complex genetic composition and high mutation frequency of SARS-CoV-2 have caused an uncertain vaccine response. Small interfering RNA (siRNA)-based therapy is an efficient strategy to control various infectious diseases employing post-transcriptional gene silencing through the silencing of target complementary mRNA. Here, we designed two highly effective shRNAs targeting the conserved region of RNA-dependent RNA polymerase (RdRP) and spike proteins capable of significant SARS-CoV-2 replication suppression. The efficacy of this approach suggested that the rapid development of an shRNA-based therapeutic strategy might prove to be highly effective in treating COVID-19. However, it needs further clinical trials.
由 SARS-CoV-2 引起的 COVID-19 在全球范围内造成了毁灭性的爆发，因此成为全球关注的健康问题。然而，目前还没有针对 COVID-19 的经过验证的、有针对性的治疗方法。已经使用了几种新兴疫苗，但保护效果并不令人满意。SARS-CoV-2 的复杂遗传组成和高突变频率导致疫苗反应不确定。基于小干扰 RNA（siRNA）的治疗是一种有效的策略，可以通过沉默靶互补 mRNA 来控制各种传染病的转录后基因沉默。在这里，我们设计了两种针对 RNA 依赖性 RNA 聚合酶（RdRP）和刺突蛋白保守区域的高效 shRNA，能够显著抑制 SARS-CoV-2 的复制。该方法的疗效表明，快速开发基于 shRNA 的治疗策略可能在治疗 COVID-19 方面非常有效。然而，还需要进一步的临床试验。
Zotero 插件
